Part 2: A single-blind, multiple-dose safety study evaluating the safety, tolerability, and pharmacokinetics of LQT-1213 in adults diagnosed with Long QT Syndrome Types 2 or 3.

Wave I is no longer recruiting. Study results are available at ClinicalTrials.gov.